Axsome Therapeutics AXSM Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's total debt?
- Axsome Therapeutics (AXSM) reported total debt of $219.9M in Q1 2026.
- How has Axsome Therapeutics's total debt changed year-over-year?
- Axsome Therapeutics's total debt increased by 4.1% year-over-year, from $211.23M to $219.9M.
- What is the long-term trend for Axsome Therapeutics's total debt?
- Over 5 years (2020 to 2025), Axsome Therapeutics's total debt has grown at a 34.2% compound annual growth rate (CAGR), from $50.12M to $218.11M.
- What does total debt mean?
- The total amount of money the company owes to lenders and creditors.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may be necessary to fund clinical trials but also raises solvency risk. A decrease indicates deleveraging or the repayment of obligations, potentially improving the balance sheet's health.
- How does total debt compare across companies?
- In the biopharmaceutical sector, total debt levels vary significantly based on the company's stage of development, with clinical-stage firms often carrying lower debt than commercial-stage peers unless they have secured significant venture debt or convertible notes.